<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347647">
  <stage>Registered</stage>
  <submitdate>28/10/2011</submitdate>
  <approvaldate>28/10/2011</approvaldate>
  <actrnumber>ACTRN12611001132932</actrnumber>
  <trial_identification>
    <studytitle>Treating Aspirin Resistance with GuidEd Therapy in Diabetes (TARGET-Diabetes) Study</studytitle>
    <scientifictitle>A pilot prospective randomized open-label blinded endpoint trial of guided antiplatelet therapy with different doses of aspirin versus clopidogrel versus metformin to reduce urinary thromboxane metabolite production in aspirin resistant people with type 2 diabetes</scientifictitle>
    <utrn>U1111-1125-5314</utrn>
    <trialacronym>TARGET-Diabetes</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>aspirin resistance</healthcondition>
    <healthcondition>type 2 diabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm 1: oral aspirin 100 mg twice per day for 12 weeks
Arm 2: oral aspirin 100 mg once per day + oral 75 mg once per day clopiodgrel for 12 weeks
Arm 3: oral aspirin 100 mg once per day + oral metformin 850 mg once per day for 12 weeks</interventions>
    <comparator>Oral aspirin 100 mg once per day for 12 weeks</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Urinary 11-dehydro thromboxane B2 : creatinine ratio</outcome>
      <timepoint>Prior to randomization (screening visit) and 12 weeks following randomization</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Major adverse cardiovascular event (MACE) including acute myocardial infarction, ischaemic stroke, coronary arterial occlusion, death. Assessed by telephone follow up and data linkage to hospital records.</outcome>
      <timepoint>1 year and 5 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Impaired fasting glucose IFG (110  125 mg / dL) or;
Impaired glucose tolerance IGT (140  199 mg / dL) or;
Type-2 diabetes (IFG &gt; 135 mg / dL or IGT &gt; 200 mg / dL)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>salicylate or thienopyridine allergy or intolerance, history of haemorrhagic stroke, aneurysm or any stroke &lt; 3 months, any thienopyridine &lt; 3 days, history of low platelet count, history of bleeding diathesis, clinical findings in the judgement of the investigator associated with increased risk of bleeding, oral anticoagulation or other antiplatelet therapy, history of withdrawal from study due to non-compliance with medication, any condition associated with poor treatment compliance, including alcoholism, mental illness, or drug dependence, investigative site personnel directly affiliated with the study or immediate family, presently enrolled in another drug study, women who are known to be pregnant, have given birth within the past 90 days, or are breast feeding, concomitant medical illness that in the opinion of the investigator is associated with reduced survival over the expected treatment period, known severe hepatic dysfunction, planned travel or other reason why participant might be unable to cooperate with protocol requirements during the study medication period.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>allocation concealment by central computer and phone randomization.</concealment>
    <sequence>computerized sequence generation</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Blinded assessment of endpoints</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/02/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>400</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>RMIT University</primarysponsorname>
    <primarysponsoraddress>Plenty Road, Bundoora, VIC 3083</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Diabetes Australia Research Trust</fundingname>
      <fundingaddress>Level 1 101 Northbourne Avenue, TURNER ACT 2612, Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Matthew Linden</sponsorname>
      <sponsoraddress>M510,
University of Western Australia,
35 Stirling Highway,
CRAWLEY, WA  6009</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>People with type 2 diabetes have both greater risk of heart attack and are likely to be resistant to drugs such as aspirin commonly used to prevent heart attacks. Furthermore, while some clinicians currently change drug therapy or increase the dose given to people with diabetes, no studies have been done to assess the risk or benefit of such action and there is a need for clear, evidence based, clinical guidelines to be established. Therefore we aim to pilot a study which will assess the effect of increasing frequency of aspirin dosing, adding alternative drug therapy, or better management of hyperglycaemia to improve markers of heart attack risk. We hypothesize that these approaches will improve markers of platelet activation in aspirin resistant diabetics.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>7/11/2011</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Matthew Linden</name>
      <address>M510,
University of Western Australia, 
35 Stirling Highway, 
CRAWLEY, WA  6009</address>
      <phone>+61893464525</phone>
      <fax>+61399257063</fax>
      <email>matthew.linden@uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Matthew Linden</name>
      <address>M510,
University of Western Australia, 
35 Stirling Highway, 
CRAWLEY, WA  6009</address>
      <phone>+61893464525</phone>
      <fax>+61399257063</fax>
      <email>matthew.linden@uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Matthew Linden</name>
      <address>M510,
University of Western Australia, 
35 Stirling Highway, 
CRAWLEY, WA  6009</address>
      <phone>+61893464525</phone>
      <fax>+61399257063</fax>
      <email>matthew.linden@uwa.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Matthew Linden</name>
      <address>M510, 
University of Western Australia,
35 Stirling Highway,
CRAWLEY, WA  6009</address>
      <phone>+61893464525</phone>
      <fax />
      <email>matthew.linden@uwa.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>